title: Epidemiology of cutaneous drug-induced reactions.
abstract: Cutaneous reactions represent in many surveillance systems, the most frequent adverse events attributable to drugs. The spectrum of clinical manifestations is wide and virtually encompasses any known dermatological disease. The introduction of biological agents and so-called targeted therapies has further enlarged the number of reaction patterns especially linked with cytokine release or in balance. The frequency and clinical patterns of cutaneous reactions are influenced by drug use, prevalence of specific conditions (e.g., HIV infection) and pharmacogenetic traits of a population, and they may vary greatly among the different populations around the world. Studies of reaction rates in cohorts of hospitalized patients revealed incidence rates ranging from, 1 out 1000 to 2 out 100 of all hospitalized patients. For drugs such as aminopenicillines and sulfamides the incidence of skin reactions is in the order of 3-5 cases out of 100 exposed people. Although the majority of cutaneous reactions are mild and self-limiting, there are reactions such as Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) which are associated with significant morbidity and mortality. Surveillance systems routed on sound epidemiologic methodology, are needed to raise signals and to assess risks associated with specific reactions and drug exposures. Identification of risk factors for adverse reactions and appropriate genetic screening of groups at higher risk may improve the outcomes of skin reactions.
authors.affiliation: Department of Dermatology Azienda Ospedaliera Papa Giovanni XXIII Bergamo, Italy - luigi.naldi@gised.it.
authors.forename: L
authors.initials: L
authors.lastname: Naldi
authors.forename: S
authors.initials: S
authors.lastname: Crotti
mesh_terms: D015331:Cohort Studies; D015897:Comorbidity; D004198:Disease Susceptibility; D003875:Drug Eruptions / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D004342:Drug Hypersensitivity / Q000453:epidemiology; D005060:Europe / Q000453:epidemiology; D005260:Female; D006748:Hospital Departments; D006801:Humans; D015994:Incidence; D007297:Inpatients; D008297:Male; D008800:Mexico / Q000453:epidemiology; D058990:Molecular Targeted Therapy / Q000009:adverse effects; D060735:Pharmacovigilance; D010787:Photosensitivity Disorders / Q000139:chemically induced / Q000453:epidemiology; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D056910:Republic of Korea / Q000453:epidemiology; D012307:Risk Factors